Results 1 to 10 of about 1,334,325 (207)

Global, regional, and national burden of asthma and its attributable risk factors from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019

open access: yesRespiratory Research, 2023
Background The burden of asthma in terms of premature death or reduced quality of life remains a huge issue. It is of great importance to evaluate asthma burden geographically and time trends from 1990 to 2019 and to assess the contributions of age ...
Zhufeng Wang   +7 more
semanticscholar   +1 more source

“Black People Like Me”: A virtual conference series to engage underserved patients with asthma in patient centered outcomes research

open access: yesResearch Involvement and Engagement, 2023
Plain English summary There are more Black people with asthma in the US than White people. Black people have more hospital stays or deaths from asthma than White people. This highlights the need for Black people to be involved in research.
LeRoy Graham   +6 more
doaj   +1 more source

Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes

open access: yesEuropean Respiratory Journal, 2021
The Global Initiative for Asthma (GINA) Strategy Report provides clinicians with an annually updated evidence-based strategy for asthma management and prevention, which can be adapted for local circumstances (e.g. medication availability).
H. Reddel   +20 more
semanticscholar   +1 more source

Investigating the impact of London’s ultra low emission zone on children’s health: children’s health in London and Luton (CHILL) protocol for a prospective parallel cohort study

open access: yesBMC Pediatrics, 2023
Background Air pollution harms health across the life course. Children are at particular risk of adverse effects during development, which may impact on health in later life.
Ivelina Tsocheva   +36 more
doaj   +1 more source

Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma.

open access: yesNew England Journal of Medicine, 2021
BACKGROUND Tezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin, an epithelial-cell-derived cytokine implicated in the pathogenesis of asthma.
A. Menzies-Gow   +13 more
semanticscholar   +1 more source

The adherence to and utility of the Global Initiative for Chronic Obstructive Lung Disease guidelines for treating COPD among pulmonary specialists: a retrospective analysis

open access: yesBMC Pulmonary Medicine, 2023
Background Despite the evidence-based guidelines promoted by the Global Initiative for Chronic Obstructive Lung Disease (GOLD), the overuse of prescription drugs to manage COPD, particularly inhaled corticosteroids (ICS), remains a persistent challenge ...
Fortune O. Alabi   +7 more
doaj   +1 more source

Sex and gender in asthma

open access: yesEuropean Respiratory Review, 2021
Asthma is a heterogenous disease, and its prevalence and severity are different in males versus females through various ages. As children, boys have an increased prevalence of asthma.
Nowrin U. Chowdhury   +3 more
semanticscholar   +1 more source

Current Understanding of Asthma Pathogenesis and Biomarkers

open access: yesCells, 2022
Asthma is a heterogeneous lung disease with variable phenotypes (clinical presentations) and distinctive endotypes (mechanisms). Over the last decade, considerable efforts have been made to dissect the cellular and molecular mechanisms of asthma ...
Nazia Habib, M. Pasha, D. Tang
semanticscholar   +1 more source

Spermidine and spermine exert protective effects within the lung

open access: yesPharmacology Research & Perspectives, 2021
Asthma is a heterologous disease that is influenced by complex interactions between multiple environmental exposures, metabolism, and host immunoregulatory processes. Specific metabolites are increasingly recognized to influence respiratory inflammation.
Marcin Wawrzyniak   +13 more
doaj   +1 more source

Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils [PDF]

open access: yes, 2017
INTRODUCTION: Asthma with adult onset and elevated blood eosinophils is a difficult-to-treat subgroup. This post hoc analysis evaluated reslizumab, an anti-interleukin-5 monoclonal antibody, in patients with late-onset eosinophilic asthma.
Brusselle, Guy   +3 more
core   +2 more sources

Home - About - Disclaimer - Privacy